Literature DB >> 4040644

Tumors and arteriovenous malformations of the spinal cord: assessment using MR.

G Di Chiro, J L Doppman, A J Dwyer, N J Patronas, R H Knop, D Bairamian, M Vermess, E H Oldfield.   

Abstract

Thirty-three patients with either primary spinal cord tumors (n = 18), intradural tumors excavating into the cord (n = 9), or spinal arteriovenous malformations (AVM) (n = 6) were studied with magnetic resonance (MR) imaging. In 25 of 38 examinations (66%) (five patients were studied twice), MR provided more information than that provided by other neuroradiologic procedures. In several cases, MR affected patient management decisions. Advantages of MR, in addition to the absence of ionizing radiation and its noninvasive nature, include good spinal cord-CSF-theca contrast, lack of bone-derived artifacts, ease of multiplanar imaging, improved discrimination between intra- and extramedullary lesions, better definition of tumoral cavities and possible distinction from true syringes, ability to help one recognize thrombus formation within an AVM, and ease of follow-up of cord lesions for possible size changes. Apart from factors precluding the study in several patients (life support systems, pacemakers, claustrophobia, neurovascular clips), disadvantages of MR imaging include motion artifacts (prevalent in thoracolumbar area), poor capability of typing and grading of tumors, potential of false-positive results, poor detection of calcification, and poor delineation of feeders and drainers of AVM.

Entities:  

Mesh:

Year:  1985        PMID: 4040644     DOI: 10.1148/radiology.156.3.4040644

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

1.  Spinal cord ganglioglioma presenting as hydrocephalus.

Authors:  G Miller; J Towfighi; R B Page
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

Review 2.  Isolated spinal neurenteric cyst presenting as intramedullary calcified cystic mass on imaging studies: case report and review of literature.

Authors:  Mateo Ziu; Prasanna Vibhute; Giacomo G Vecil; James Henry
Journal:  Neuroradiology       Date:  2009-11-28       Impact factor: 2.804

3.  Spinal dural arteriovenous malformations with perimedullary drainage. Indications and results of surgery in 30 cases.

Authors:  K L Mourier; F Gelbert; A Rey; E Assouline; B George; D Reizine; J J Merland; J Cophignon
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  Clinical applications of magnetic resonance imaging of the spine.

Authors:  H Firooznia; M Rafii; C Golimbu
Journal:  Bull N Y Acad Med       Date:  1988-11

5.  Magnetic resonance imaging in vascular malformations: studies with and without gadolinium-DTPA.

Authors:  F Koschorek; B Terwey
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

6.  Early Disappearance of Cord Signal Changes Following Endovascular Treatment of a Spinal Dural AV Fistula.

Authors:  G S Srikanth; D Sivakumar; N P Jayakumar; M Veerendrakumar; M Thomas
Journal:  Interv Neuroradiol       Date:  2005-10-26       Impact factor: 1.610

7.  Cystic spinal cord tumors: magnetic resonance imaging correlated to histopathological findings.

Authors:  H Matsui; M Kanamori; K Yudoh; K Ohmori; T Yasuda; K Wakaki
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

8.  MR imaging of intraspinal tumors--capability in histological differentiation and compartmentalization of extramedullary tumors.

Authors:  K Takemoto; Y Matsumura; H Hashimoto; Y Inoue; T Fukuda; M Shakudo; Y Nemoto; Y Onoyama; T Yasui; A Hakuba
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

Review 9.  Magnetic resonance imaging of the brain and spine.

Authors:  D M Hadley; G M Teasdale
Journal:  J Neurol       Date:  1988-03       Impact factor: 4.849

10.  Magnetic resonance diagnosis of intramedullary tumors of the spinal cord.

Authors:  G Scotti; G Scialfa; N Colombo; L Landoni
Journal:  Neuroradiology       Date:  1987       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.